



## Search Results for Google

 [Print this Release](#)

October 04, 2007 03:30 AM Eastern Daylight Time

### **NeoStem Announces Online Availability of In-Depth Article Written by CEO Detailing Burgeoning Adult Stem Cell Industry**

#### **Article in Stem Cell Summit Publication Highlights Growing Need for Company's Next Generation Biomedical Services**

NEW YORK--(BUSINESS WIRE)--NeoStem, Inc. (AMEX:NBS), the first company to specialize in the collection, processing and storage of stem cells from healthy adults for personal use in times of critical medical need, has announced the online availability of an article written by Robin Smith, M.D., Chief Executive Officer of NeoStem, detailing the latest progress and opportunities in the burgeoning field of adult stem cell therapeutics. The article was published in the official publication, "Stem Cell Report," distributed at this year's Stem Cell Summit in Boston.

"According to various market experts, new FDA-approved stem cell based therapies should be available to you and your doctor in five to 10 years, so unless you are an octogenarian, probabilities are that you could benefit from adult autologous stem cell banking services," said the article, titled "Is Long-Term Autologous Adult Stem Cell Banking a New Form of Insurance?"

Today, Dr. Smith took part in one of the Summit's "Conversations with Experts," a series of roundtables focusing on business, economic, political and therapeutic strategies. Topics discussed included NeoStem's experience and progress to advance collaborations between adult stem cell storage companies and physicians, hospitals and biopharma to realize the promise of adult stem cell innovation.

"According to Frost & Sullivan, one of the world's premier medical research firms, the global market for stem cell therapy is expected to be \$20 billion by 2010 (the equivalent of 20 "blockbuster" drugs)," said the article. "This number is supported by NIH statistics that suggest there are over 700 clinical trials underway relating to adult stem cells."

"It is always an honor to be featured in a publication that will be read by some of our industry's most influential leaders," said Dr. Smith. "I believe that this article portrays the opportunities and challenges that face all of us as we move into the next exciting phase of development, both for the industry as a whole and for NeoStem as leader within the industry. I invite all of our investors and other interested parties to read through the article to get a better understanding of the groundbreaking work that is being done in the hope of benefiting those afflicted with some of today's most devastating diseases."

NeoStem's proprietary technology positions the company at the forefront of a bold new shift in the medical industry where the patient's own body would provide the materials, such as adult stem cells, necessary to formulate therapies that have, until recently, been provided by pharmaceutical companies in the form of synthetic, chemically engineered drugs. Although adult stem cell therapies are generally not standard of care, the Company believes medicine is on the threshold of a plethora of such new therapies.

To read the entire article please visit <http://www.trilogy-capital.com/tcp/neostem/>.

#### About NeoStem, Inc.

NeoStem is a biotechnology services company enhancing the delivery of adult stem cell therapeutics to health-conscious consumers. The Company is developing a nationwide network of adult stem cell collection centers, enabling people to donate and store their own stem cells with NeoStem for personal use years or decades later in times of critical medical need. Although adult stem cell therapies are generally not standard of care, the Company believes medicine is on the threshold of a plethora of such new therapies.

The proprietary NeoStem technologies empower health-conscious consumers to help protect their future health by undergoing treatment with their own stem-cells - providing an accessible supply of healthy, genetically matched stem cells for use in the eventuality of illness.

Currently underway are hundreds of stem cell-based research programs and clinical trials investigating the use of these non-controversial adult stem cells, such as those collected from donors under NeoStem's methods. As the nation's population ages and encounters serious age-related and congenital health issues, NeoStem has positioned itself as a leader in the national trend toward protecting one's future health.

The Company's business plan is a service model that is completely scalable, thus minimizing risk levels ordinarily related to most long-term biopharmaceutical research and development. Under its strategic business plan, NeoStem has begun opening a nationwide network of adult stem cell collection facilities. Its stem cell collection systems will be located in existing physician offices and medical facilities, where the procedures and care can be administered by trusted personal doctors and medical professionals.

For more information, please visit: [www.neostem.com](http://www.neostem.com).

For other information and resources about the Company, visit [www.CFSG1.com](http://www.CFSG1.com) or [www.trilogy-capital.com/tcp/neostem/quote.html](http://www.trilogy-capital.com/tcp/neostem/quote.html).

#### Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the ability of NeoStem, Inc. ("the Company") to develop the adult stem cell business, the future of regenerative medicine and the role of adult stem cells in that future, the future use of adult stem cells as a treatment option and the potential revenue growth of the Company's business. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company's ability to enter the adult stem cell arena, its success in such arena and future operating results are dependent upon many factors, including but not limited to (i) the Company's ability to obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) the Company's ability to build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; (iv) scientific and medical developments beyond the Company's control; (v) the Company's inability to obtain appropriate state licenses or any other adverse effect or limitations caused by government regulation of the business; (vi) whether any of the Company's current or future patent applications result in issued patents; and (vii) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission which are available for review at [www.sec.gov](http://www.sec.gov) under "Search for Company Filings."

Pursuant to an October 1, 2006 agreement, Consulting For Strategic Growth I, Ltd. ("CFSG1") provides the Company with consulting,

business advisory, investor relations, public relations and corporate development services, for which CFSG1 receives a fixed monthly fee for the duration of the agreement and received shares of NeoStem's common stock. Independent of CFSG1's receipt of cash or other compensation from the Company, CFSG1 may choose to purchase the common stock of the Company and thereafter sell those shares at any time it deems appropriate to do so. For more information, please visit [www.cfsg1.com](http://www.cfsg1.com).

#### Contacts

NeoStem, Inc.

Robin Smith, Chief Executive Officer,

212-584-4180

[rsmith@neostem.com](mailto:rsmith@neostem.com)

[www.neostem.com](http://www.neostem.com)

or

Consulting for Strategic Growth 1

Stanley Wunderlich/Daniel Stepanek,

800-625-2236

Fax: 212-337-8089

<http://www.cfsg1.com>

or

Financial Communications

Trilogy Capital Partners

Ryon Harms, 800-592-6067

[ryon@trilogy-capital.com](mailto:ryon@trilogy-capital.com)

#### Sharing



[Digg](#)



[del.icio.us](#)



[Newsvine](#)



[Reddit](#)



[Print this Release](#)